1	Effect of nasal carriage of <i>Bacillus</i> species on COVID-19 severity:
2	A cross-sectional study
3	Muinah A. Fowora, <sup>a#</sup> Adenike Aiyedogbon, <sup>a</sup> Ibilola Omolopo, <sup>a</sup> Ahmed O. Tajudeen, <sup>a</sup> Abdul-
4	Lateef Olanlege, <sup>b</sup> Adefunke Abioye, <sup>b</sup> Grace B. Akintunde, <sup>a</sup> Morenike O. Folayan, <sup>c</sup> Babatunde L.
5	Salako <sup>a</sup>
6	<sup>a</sup> Molecular Biology and Biotechnology Department, Nigerian Institute of Medical Research,
7	Yaba, Lagos, Nigeria
8	<sup>b</sup> Infectious Diseases Hospital, Lagos, Nigeria
9	<sup>c</sup> Department of Child Dental Health, College of Health Sciences, Obafemi Awolowo University
10 11 12	Running Head: Bacillus species in the nasopharynx and COVID-19
13	
14	#Address correspondence to Muinah A. Fowora, muinahj@yahoo.com
15	
16	
17	ABSTRACT
18	Intranasal sprays containing Bacillus species are being researched for treating viral respiratory
19	tract infections. The aim of this study was to assess the relationship between the nasal carriage of
20	Bacillus and COVID-19 severity. This was a cross-sectional study that collected nasopharyngeal
21	samples from adults 18 years and above visiting two COVID-19 testing centers in Lagos, Nigeria
22	between September 2020 and September 2021. Bacillus species were cultured from the

respiratory samples and confirmed using molecular methods. The dependent variable was

24 COVID-19 status classified as negative, asymptomatic, mild, or severe. The independent variable was the nasal carriage of *Bacillus* species. Multinomial regression analysis was done to 25 determine the association between nasal carriage of Bacillus and COVID-19 severity after 26 adjusting for age, sex, and co-morbidity status. About 388 participants were included in the study 27 with a mean (standard deviation) age of 40.05 (13.563) years. The majority (61.1%) of the 28 participants were male, 100 (25.8%) had severe COVID-19, 130 (33.5%) had pre-existing 29 comorbidity, and 76 (19.6%) had Bacillus cultured from their nasopharyngeal specimen. Bacillus 30 species presence was significantly associated with higher odds of severe COVID-19 compared to 31 32 having a negative COVID-19 status. However, the presence of *Bacillus* species was significantly associated with lower odds of severe COVID-19 compared to having a mild COVID-19 status. 33 The study suggests that nasal carriage of Bacillus species may substantially impact the clinical 34 course of COVID-19. This study supports the exploration of Bacillus species in the prevention 35 and management of viral respiratory tract infections. 36

# **37 IMPORTANCE**

With the introduction of intranasal spray containing *Bacillus* species for the treatment of viral respiratory tract infections, such as COVID-19 and respiratory syncytial virus, identifying the association between the nasal carriage of *Bacillus* species and COVID-19 susceptibility and severity will help further substantiate the investigation of these bacteria for COVID-19 prevention and treatment. This study evaluated the association between the carriage of *Bacillus* species in the nasopharyngeal tract and COVID-19 severity and found that the presence of *Bacillus* species in the nasopharynx may significantly impact the clinical course of COVID-19.

45

#### 47 BACKGROUND

Corona Virus Disease 2019 (COVID-19), an acute and highly infectious respiratory disease 48 49 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the 50 death of more than 6.42 million people globally since its outbreak in Wuhan, China in 2019 [1]. Several factors such as the nasal microbiota determine the susceptibility and severity of the 51 52 disease [2-7]. Microbiota can confer some level of protection on the host against some diseases 53 by creating a unique microbial ecosystem that enhances resistance against the manifestation of respiratory tract infection caused by bacterial, fungal, and/or viral pathogens [8, 9]. It also serves 54 as markers of disease [10] and the regulation of local and systemic immunity in the 55 nasopharyngeal tract thereby influencing COVID-19 susceptibility and clinical outcome [7]. In 56 57 addition, viral infection modifies the host's nasal microbiota, decreases the nasal and gut microbiota diversity, and increases the disease infectivity and severity [11, 12]. 58

A significant increase in bacteria belonging to the phyla Bacteroides, Proteobacteria, 59 Actinobacteria, Firmicutes, and Fusobacteria have been reported among COVID-19 patients [13] 60 though some other study did not find a significant difference in the nasal bacterial composition 61 and diversity in patients with COVID-19 when compared with patients negative for COVID-19 62 [14]. The members of bacteria belonging to the phylum Firmicutes, especially of the class 63 Bacilli, have been associated with respiratory immunity and strengthening the host defense 64 against respiratory viral infections [11]. Bacillus has been explored as intranasal sprays for the 65 treatment of viral infection [15, 16] as it eases the symptoms of acute respiratory tract infection 66 caused by respiratory syncytial virus by reducing the viral load and inflammation associated with 67 68 the disease [16]. Bacillus subtilis possesses the probiotic potential to increase mucosal and tonsillar immunity against respiratory diseases through the formation of immune cells in the 69

nasal cavity and tonsil [15]. Like bacilli intranasal sprays, lactobacilli-containing throat sprays
have also been demonstrated to considerably lessen the acute symptoms of COVID-19 as well as
the load of the virus in the nasopharynx [17]. However, there are currently no studies showing
the effect of nasal carriage of *Bacillus* species on the susceptibility to SARS-CoV-2 infection and
severity.

The aim of this study was to determine the association between nasal carriage of *Bacillus species* and COVID-19 susceptibility and severity. We hypothesize that there will be a negative association between nasal carriage of *Bacillus* and COVID-19 susceptibility and severity.

78 METHODS

# 79 Study design and population

This study was a cross-sectional study that compared the prevalence of nasal carriage of *Bacillus* 80 species among adult who were tested positive or negative for COVID-19 in Lagos State, Nigeria. 81 The study population included individuals  $\geq 18$  years, who present for SARS-CoV-2 testing at 82 the COVID-19 modified drive-through centre of the Nigerian Institute of Medical Research and 83 the laboratory of the Infectious Disease Hospital, Lagos. The participants were recruited between 84 September 2020 to September 2021. Adults who had travelled out of the country in the last one 85 month of the survey were excluded from the study. Informed consents were appropriately 86 obtained from all eligible participants. 87

# 88 Sample size and sampling technique

The sample size for this study was determined using the formula for sample size calculations for prevalence studies [18]. The standard normal variate was set at 5% type I error; the precision was set at 0.05; and the expected proportion of adults with nasal *Bacillus* was set at 50% in the absence of any available data. The minimum sample size was 385. The sample size was
increased to 450 participants to account for missing data or invalid COVID-19 results. A
convenient sample of participants willing to participate in the study was recruited.

### 95 **Data collection**

96 Information on the age (age as at last birthday) and sex (sex at birth) of participants were 97 collected. Other information collected were the symptoms and severity of the patient and if the 98 participant had any underlying conditions such as diabetes, asthma, hypertension, heart, lung, 99 and kidney disease. These variables had been identified factors that influence COVID-19 100 susceptibility and severity [19, 20]. No identifying information was collected from the participants.

102 Participants were classified as positive for COVID-19 when the results on the real-time reverse transcription-polymerase-chain-reaction (RT-PCR) assay of their nasopharyngeal swab 103 specimens was positive. Participants with positive test results were categorized as asymptomatic, 104 mild or severe cases using the guidelines of the Nigeria Centre for Disease Control and the 105 National Institute of Health [21, 22]. Asymptomatic cases were defined as patients that had no 106 symptoms specific to COVID-19 but tested positive SARS-CoV-2. Mild cases were patients who 107 had symptoms corresponding to COVID-19 such as fever (<38<sup>0</sup>C), cough, sore throat, malaise, 108 headache, muscle pain, loss of taste and smell, nausea, vomiting, diarrhea, abdominal pain, but 109 do not have difficulty breathing, dyspnea and any underlying conditions. Severe cases were 110 patients with clinical manifestations of COVID-19 in conjunction with difficulty in breathing, 111 reduced/decreased breath sounds, dullness in percussion, increased or decreased vocal resonance, 112 113 and presence of an underlying comorbid condition such as diabetes, asthma, hypertension, heart, lung, asthma and kidney disease. 114

### **116** Sample collection and analysis

117 Nasopharyngeal swab samples were collected from the participants into two different transport 118 media. One containing a viral transport medium (VTM) and the other a bacterial transport 119 medium containing Tryptone soy broth buffered with 2.5% saline and 10% glycerol. All samples 120 were analyzed within one to two hours of specimen collection.

#### 121 RNA extraction and qRT-PCR

Viral Nucleic acid Extraction was carried out on the nasopharyngeal sample in VTM using the Qiagen Viral Extraction kit according to manufacturer's instructions, and SARS-CoV-2 was detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR) using a commercial Nucleic Acid Diagnostic Kit for COVID-19, Sansure Novel Coronavirus (2019nCoV), according to manufacturer's protocol (Sansure Biotech Inc). The Sansure kit has high sensitivity and is endorsed for the SARS-CoV-2 testing [23].

## 128 Bacteria isolation

The nasopharyngeal samples in the bacteria transport medium were plated on Mueller Hinton Agar and de Man-Rogosa Sharpe (MRS) agar (Oxoid, USA) using a disposable loop. The nutrient agar was incubated aerobically at 37<sup>0</sup>C for 24 hours while the MRS agar was incubated at 37<sup>0</sup>C under anaerobic conditions using a anaerobic jar containing an anaerobic gas generating pack (Thermo Scientific<sup>™</sup> Oxoid<sup>™</sup> AnaeroGen<sup>™</sup>) for 48 to 72 hours.

### 134 Bacterial identification

Isolates were identified based on the morphological characteristics of the colony and using both
phenotypic and molecular methods. The phenotypic based methods included Gram staining,
nitrate reduction, gelatin hydrolysis, and citrate utilization as previously described [24, 25].

138 Deoxyribonucleic acid (DNA) was extracted from all the presumptively identified bacteria using the NIMR Biotech DNA extraction kit. To confirm the identification of the Bacillus species, 139 140 polymerase chain reaction amplification of the 16s rRNA gene specific for Bacillus was carried out. The reaction was done using the primer set 16S-HV (Forward primer -5'-141 TGTAAAACGACGGCCAGTGCCTAATACATGCAAGTCGAGCG-3' and Reverse primer-142 5'-CAGGAAACAGCTATGACCACTGCTGCCTCCCGTAGGAGT-3') previously 143 as described [26]. 144

Polymerase chain reaction was done using the Solis Biodyne 5X HOT FIREPol Blend Master
mix in a 20 µl reaction mixture, containing 1X Blend Master mix buffer (Solis Biodyne), 1.5
mM MgCl2, 200µM of each deoxynucleoside triphosphates (dNTP)(Solis Biodyne), 25pMol of
each primer (BIOMERS, Germany), 2 unit of Hot FIREPol DNA polymerase (Solis Biodyne),
Proofreading Enzyme, 5µl of the extracted DNA, and sterile nuclease- free water was used to
make up the reaction mixture.

Thermal cycling was conducted in a PTC 200 gradient thermal Cycler Eppendorf for an initial denaturation of 95°C for 15 minutes followed by 35 amplification cycles of 30 seconds at 95°C, one minute at 58°C and one minute 30 Seconds at 72°C. This was followed by a final extension step of 10 minutes at 72°C. The amplification product was separated on a 1.5% agarose gel and electrophoresis was carried out at 80V for 1 hour 30 minutes. After electrophoresis, DNA bands were visualized by ethidium bromide staining. 100bp DNA ladder was used as DNA molecular weight standard.

# 158 STATISTICAL ANALYSIS

The study variables were presented as means (standard deviations) or frequencies and percentages. A multivariate logistic regression model was developed to determine the association between COVID-19 status (negative, asymptomatic, mild and severe) and *Bacillus* species isolation status dichotomized into positive and negative. The model was adjusted for age, sex, and presence of comorbidity. Statistical analysis was done using SPSS version 26.0 and statistical significance was set at a p value  $\leq 0.05$ .

### **165 ETHICAL CONSIDERATIONS**

Ethical approval was obtained from the Institutional Review Board of the Nigerian Institute of Medical Research (IRB/20/043). A written informed consent was obtained from all the participants following the national ethics guidelines [27].

# 169 **RESULTS**

There were 450 study participants recruited into this study. Forty-three (9.6%) had invalid COVID-19 qRT-PCR and the information on the age and/or sex was missing for 19 (4.2%) participants. The complete data for 388 participants is presented in Table 1.

The age of participants ranged from 18 to 75 years with the mean age (standard deviation) age of 40.05 (13.563) years. Also, 237 (61.1%) participants were male, 228 (58.8%) had a negative COVID-19 test result and 258 (66.5%) had no pre-existing medical condition. Among participants that reported having a pre-existing condition, 71 (18.3%) had high blood pressure and 22 (5.7%) had both type II diabetes mellitus and high blood pressure. There were *Bacillus* species isolated from 76 (19.6%) of the nasopharyngeal samples collected. 179 Table 1. Age, sex, COVID-19 severity, pre-existing conditions, and *Bacillus* isolation from the

180	nasopharyngeal	samples of adu	It Nigerians w	ith COVID-19 (	N = 388)
			<u> </u>		· · · · · · · · · · · · · · · · · · ·

Factor	Variable	Statistic
Sex	Female: n (%)	151 (38.9)
	Male: n (%)	237 (61.1)
Age	Mean (SD)	40.05 (13.563)
COVID-19	Negative n (%)	228 (58.8)
	Asymptomatic n (%)	28 (7.2)
	Mild n (%)	32 (8.2)
	Severe n (%)	100 (25.8)
Pre-existing Condition	Yes n (%)	130 (33.5)
	No n (%)	258 (66.5)
Type of pre-existing		
condition	None n (%)	258 (66.5)
	Asthma n (%)	15 (3.9)
	Diabetes n (%)	14 (3.6)
	Hepatitis B n (%)	3 (0.8)
	High blood pressure/Hypertension n (%)	71 (18.3)
	Rhinosinusitis n (%)	1 (0.3)
	Diabetes and High Blood Pressure n (%)	22 (5.7)
	Ulcer n (%)	4 (1.0)
Bacillus isolated	No n (%)	312 (80.4%)
	Yes n (%)	76 (19.6)

Table 2 shows that the presence of *Bacillus* species in the nasopharyngeal samples was also associated with COVID-19 severity: patients with *Bacillus* species in the nasopharyngeal samples had significantly higher odds for severe COVID-19 than a negative COVID-19 result (AOR = 3.347, 95% CI: 1.359, 8.243). Also, patients with *Bacillus* species in the nasopharyngeal samples had significantly lower odds for severe COVID-19 than a mild COVID-19 result (AOR = 0.158, 95% CI: 0.055, 0.455).

Table 2. Associations between Age, comorbidity, and the presence of nasal carriage of *Bacillus* species and COVID-19 Severity (N = 388).

	Severe vs. N	egative	Severe vs. Asym	ptomatic	Severe vs.	Mild
Variable	AOR (95% CI)	Р	AOR (95% CI)	р	AOR (95% CI)	Р
					0.891	
	0.912		0.928		(0.849,	
Age	(0.884, 0.941)	<0.001*	(0.884, 0.973)	0.002*	0.9340.183)	<0.001*
	0.645		0.951		0.518	
Sex	(0.325, 1.282)	0.211	(0.324, 2.789)	0.927	(0.197, 1.365)	0.183
Presence of a	0.587				0.7529	
co-morbidity	(0.495, 0.696)	<0.001*	-	-	(0.561, 0.947)	0.018*
	3.347		0.381		0.158	
Bacillus	(1.359, 8.243)	0.009*	(0.123, 1.182)	0.095	(0.055, 0.455)	0.001*
AOR: Adjusted odds ratio; B: CI: Confidence interval; *: Statistically significant at P< 0.05. The reference						
category is severe.						

#### 192 Discussion

The objective of this study was to determine if there was an association between the nasal carriage of *Bacillus* species and COVID-19 severity. The study findings showed a strong positive association between nasal carriage of *Bacillus* species and COVID-19 severity while participants who carried *Bacillus* species in their upper respiratory tract had a lower likelihood of developing severe COVID-19 when compared with mild cases. The study findings did not support the study hypothesis of a negative relationship between nasal carriage of *Bacillus* species and COVID-19 severity.

This is the first study showing a relationship between bacteria co-infection involving nasal 200 carriage of *Bacillus* species and COVID-19. The *Bacillus* species isolated in this study can be 201 202 classified as a co-infection as they were recovered from the participants at the point of SARS-CoV-2 infection diagnosis [37]. Our study results indicated that attention needs to be given to 203 Bacillus species as a secondary bacterial co-infection in COVID-19 and a possible risk factor for 204 severe COVID 19. Prior studies that evaluated respiratory bacteria co-infection in patients with 205 COVID-19 identified Acinetobacter baumannii, Staphylococcus 206 aureus, Klebsiella pneumoniae and Staphylococcus aureus as the most isolated bacterial infection from respiratory 207 tract cultures [38-40]. We had also reported an association between the nasal carriage 208 of Moraxella catarrhalis and Chlamydophila pneumoniae and COVID-19 [41]. 209

The observed association between *Bacillus species*, a respiratory opportunistic pathogen, and the severity of COVID-19 may be connected to its association with the high risk for co-morbidities in patients with severe COVID-19. *Bacillus* counts are high in patients who are immunocompromised and patients with diabetes [28, 30-32]. These co-morbidities increase the risk for severe COVID-19. The study finding may influence the development of nasal sprays for the treatment of respiratory viral infections [15, 16]. There is still a need to further identify (up to strain level) the *Bacillus* species isolated and characterize the isolates by antibiotic susceptibility and virulence to better understand the properties of the isolates that may influence the severity of COVID-19.

We also found that individuals with Bacillus species in their upper respiratory tract may have a 219 220 lower likelihood of developing severe COVID-19 when compared with mild cases. This finding 221 is similar to the outcome of a prior study that demonstrated that treatment with lactobacilli had the potential to lower the viral load of SARs-COV-2 in the upper respiratory tract without 222 223 necessarily resolving the symptoms of COVID-19 [17]. The lower likelihood of severe COVID-19 compared to mild COVID-19 when Bacillus is present may also be related to the reduction or 224 225 improvement of the symptoms of SARs-COV-2 infection by the Bacillus species. Metabolites, 226 such as surfactins, iturin A, and fengycins produced by some Bacillus species have antibacterial and antifungal activities [33-36]. These metabolites may be responsible in easing the symptoms 227 228 of COVID-19 and preventing the progression of the severity of the disease in mild cases of COVID-19. There is a need to further substantiate this result in a prospective study. 229

This study has its limitations. The cross-sectional study design used limits the generalizability of 230 the results and can only suggest an association and not a cause-effect relationship. The use of 231 nasopharyngeal respiratory tract cultures also limits the interpretation of this findings as upper 232 respiratory tract samples are more subject to contamination and commensal pathogens, and thus 233 bacterial isolation from such specimen are often higher than those from blood cultures [38]. We 234 could not collect specimen from the lower respiratory tract of the participants in this study as 235 236 most of the participants did not have a productive cough. However, there is a need for further study to determine the pathogenicity of the *Bacillus* species and the role this plays in COVID-19 237

severity. The use of lower respiratory tract specimen and/or blood culture should also be
explored to further validate the association between *Bacillus* species co-infection and COVID-19
severity.

# 241 CONCLUSION

This study suggests that the presence of *Bacillus* species in the nasopharyngeal tract could significantly influence the clinical progression or severity of COVID-19. This study supports the exploration of *Bacillus* species in the prevention and management of COVID-19.

# 245 ACKNOWLEDGMENTS

This study was funded with funds from the Nigeria Institute of Medical Research (NMG-CIF-18-0036) and the early career research grant of the Royal Society of Tropical Medicine and Hygiene.

We also thank Rukayat Raji and Khadijah Sanusi for their laboratory support, and the LagosState Ministry of Health.

251

#### 252 **REFERENCES**

- 1. Coronavirus disease (COVID-19) pandemic.7 Mar 2023.
- 254 https://www.who.int/europe/emergencies/situations/covid-19
- Jochems SP, Ferreira DM, Smits HH. 2021. Microbiota and compartment matter in the
   COVID-19 response. Nat Immunol 22:1350–1352.
- 257 3. Rueca, M., Fontana, A., Bartolini, B., Piselli, P., Mazzarelli, A., Copetti, M., Binda, E., Perri,
- 258 F., Gruber, C. E. M., Nicastri, E., Marchioni, L., Ippolito, G., Capobianchi, M. R., Di Caro,

	259	A., Pazienza,	V. 2021.	Investigation of	of Nasal/Oro	pharyngeal	Microbial	Community of
--	-----	---------------	----------	------------------	--------------	------------	-----------	--------------

260 COVID-19 Patients by 16S rDNA Sequencing. Int J Environ Res Public Health 18(4), 2174.

- 4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y,
- Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. 2020. Clinical course and risk factors for
- 263 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
- Lancet 395(10229), 1054–1062
- 265 5. Severe Covid-19 GWAS Group; Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A,
- 266 Invernizzi P, Fernández J, Prati D, Baselli G, Asselta R, Grimsrud MM, Milani C, Aziz F,
- 267 Kässens J, May S, Wendorff M, Wienbrandt L, Uellendahl-Werth F, Zheng T, Yi X, de
- 268 Pablo R, Chercoles AG, Palom A, Garcia-Fernandez AE, Rodriguez-Frias F, Zanella A,
- Bandera A, Protti A, Aghemo A, Lleo A, Biondi A, Caballero-Garralda A, Gori A, Tanck A,
- 270 Carreras Nolla A, Latiano A, Fracanzani AL, Peschuck A, Julià A, Pesenti A, Voza A,
- Jiménez D, Mateos B, Nafria Jimenez B, Quereda C, Paccapelo C, Gassner C, Angelini C,
- 272 Cea C, Solier A, Pestaña D, Muñiz-Diaz E, Sandoval E, Paraboschi EM, Navas E, García
- 273 Sánchez F, Ceriotti F, Martinelli-Boneschi F, Peyvandi F, Blasi F, Téllez L, Blanco-Grau A,
- 274 Hemmrich-Stanisak G, Grasselli G, Costantino G, Cardamone G, Foti G, Aneli S, Kurihara
- 275 H, ElAbd H, My I, Galván-Femenia I, Martín J, Erdmann J, Ferrusquía-Acosta J, Garcia-
- 276 Etxebarria K, Izquierdo-Sanchez L, Bettini LR, Sumoy L, Terranova L, Moreira L, Santoro
- 277 L, Scudeller L, Mesonero F, Roade L, Rühlemann MC, Schaefer M, Carrabba M, Riveiro-
- 278 Barciela M, Figuera Basso ME, Valsecchi MG, Hernandez-Tejero M, Acosta-Herrera M,
- 279 D'Angiò M, Baldini M, Cazzaniga M, Schulzky M, Cecconi M, Wittig M, Ciccarelli M,
- 280 Rodríguez-Gandía M, Bocciolone M, Miozzo M, Montano N, Braun N, Sacchi N, Martínez
- N, Özer O, Palmieri O, Faverio P, Preatoni P, Bonfanti P, Omodei P, Tentorio P, Castro P,

282		Rodrigues PM, Blandino Ortiz A, de Cid R, Ferrer R, Gualtierotti R, Nieto R, Goerg S,
283		Badalamenti S, Marsal S, Matullo G, Pelusi S, Juzenas S, Aliberti S, Monzani V, Moreno V,
284		Wesse T, Lenz TL, Pumarola T, Rimoldi V, Bosari S, Albrecht W, Peter W, Romero-Gómez
285		M, D'Amato M, Duga S, Banales JM, Hov JR, Folseraas T, Valenti L, Franke A, Karlsen TH.
286		2020. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J
287		Med 383(16):1522-1534.
288	6.	Göker H, Aladağ Karakulak E, Demiroğlu H, Ayaz Ceylan ÇM, Büyükaşik Y, Inkaya AÇ,
289		Aksu S, Sayinalp N, Haznedaroğlu IC, Uzun Ö, Akova M, Özcebe OI, Ünal S. 2020. The
290		effects of blood group types on the risk of COVID-19 infection and its clinical outcome.
291		Turk J Med Sci 50(4):679-683.
292	7.	Smith N, Goncalves P, Charbit B, Grzelak L, Beretta M, Planchais C, Bruel T, Rouilly V,
293		Bondet V, Hadjadj J, Yatim N, Pere H, Merkling SH, Ghozlane A, Kernéis S, Rieux-Laucat
294		F, Terrier B, Schwartz O, Mouquet H, Duffy D, Di Santo JP. 2021. Distinct systemic and
295		mucosal immune responses during acute SARS-CoV-2 infection. Nat Immunol 22(11):1428-
296		1439
297	8.	Brugger SD, Bomar L, Lemon KP. 2016. Commensal-pathogen interactions along the human
298		nasal passages. PLoS Pathog 12: e1005633
299	9.	Bosch AATM, de Steenhuijsen Piters WAA, van Houten MA, Chu MLJN, Biesbroek G,
300		Kool J, Pernet P, de Groot PCM, Eijkemans MJC, Keijser BJF, Sanders EAM, Bogaert D.
301		2017. Maturation of the Infant Respiratory Microbiota, Environmental Drivers, and Health
302		Consequences. A Prospective Cohort Study. Am J Respir Crit Care Med 196(12):1582-1590.
303	10	. Liu J, Liu S, Zhang Z, Lee X, Wu W, Huang Z, Lei Z, Xu W, Chen D, Wu X, Guo Y, Peng
304		L, Lin B, Chong Y, Mou X, Shi M, Lan P, Chen T, Zhao W, Gao Z. 2021. Association

305	between the nasopharyngeal microbiome and metabolome in patients with COVID-19. Synth
306	Syst Biotechnol 6(3):135-143.
307	11. Sencio V, Machado MG, Trottein F. 2021. The lung-gut axis during viral respiratory
308	infections: the impact of gut dysbiosis on secondary disease outcomes. Mucosal Immunol
309	14(2):296-304.
310	12. Dimitri-Pinheiro S, Soares R, Barata P. 2020. The microbiome of the nose-friend or foe?
311	Allergy Rhinol (Providence) 11: 2152656720911605. doi:10.1177/2152656720911605
312	13. Kolhe R, Sahajpal NS, Vyavahare S, Dhanani AS, Adusumilli S, Ananth S, Mondal AK,
313	Patterson GT, Kumar S, Rojiani AM, Isales CM, Fulzele S. 2021. Alteration in
314	Nasopharyngeal Microbiota Profile in Aged Patients with COVID-19. Diagnostics (Basel)
315	11(9):1622.
316	14. De Maio F, Posteraro B, Ponziani FR, Cattani P, Gasbarrini A, Sanguinetti M. 2020.
317	Nasopharyngeal Microbiota profiling of SARS-CoV-2 infected patients. Biol Proced Online
318	22:18.
319	15. Yang Y, Jing Y, Yang J, Yang Q. 2018. Effects of intranasal administration with Bacillus
320	subtilis on immune cells in the nasal mucosa and tonsils of piglets. Exp Ther Med 15: 5189–
321	5198.
322	16. Tran DM, Tran TT, Phung TTB, Bui HT, Nguyen PTT, Vu TT, Ngo NTP, Nguyen MT,
323	Nguyen AH, Nguyen ATV. 2022. Nasal-spraying Bacillus spores as an effective
324	symptomatic treatment for children with acute respiratory syncytial virus infection. Sci Rep
325	12(1):12402.
326	17. De Boeck I, Cauwenberghs E, Spacova I, Gehrmann T, Eilers T, Delanghe L, Wittouck S,

327 Bron PA, Henkens T, Gamgami I, Simons A, Claes I, Mariën J, Ariën KK, Bakokimi D,

328	Loens K, Jacobs K, Ieven M, Bruijning-Verhagen P, Delputte P, Coenen S, Verhoeven V,
329	Lebeer S. 2022. Randomized, Double-Blind, Placebo-Controlled Trial of a Throat Spray with
330	Selected Lactobacilli in COVID-19 Outpatients. Microbiol Spectr 10(5):e0168222
331	18. Arya R, Antonisamy B, Kumar S. 2012. Sample size estimation in prevalence studies. Indian
332	J Pediatr. 79: 1482–1488.
333	19. Erinoso OA, Wright KO, Anya S, Bowale A, Adejumo O, Adesola S, Osikomaiya B, Mutiu
334	B, Saka B, Falana A, Ola-Ayinde D, Akase EI, Owuna H, Abdur-Razzaq H, Lajide D, Ezechi
335	O, Ogboye O, Osibogun A, Abayomi A. 2020. Clinical characteristics, predictors of
336	symptomatic coronavirus disease 2019 and duration of hospitalisation in a cohort of 632
337	Patients in Lagos State, Nigeria. Niger Postgrad Med J 27(4):285-292.
338	20. Shoaib N, Noureen N, Munir R, Shah FA, Ishtiaq N, Jamil N, Batool R, Khalid M, Khan I,
339	Iqbal N, Zaidi N. 2021. COVID-19 severity: Studying the clinical and demographic risk
340	factors for adverse outcomes. PLoS One. 16(8):e0255999.
341	21. Federal Ministry of Health & Nigeria Centre for Disease Control, National Interim
342	Guidelines for Clinical Management of COVID-19. 2020.
343	https://covid19.ncdc.gov.ng/media/files/National_Interim_Guidelines_for_Clinical_Manage
344	ment_of_COVID-19_v3.pdf
345	22. Clinical spectrum. In: COVID-19 Treatment Guidelines [Internet]. [cited 7 Mar 2023].
346	https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
347	23. Freire-Paspuel B, Garcia-Bereguiain MA. 2021. Clinical performance and analytical
348	sensitivity of three SARS-CoV-2 nucleic acid diagnostic tests. Am J Trop Med Hyg 104:
349	1516–1518.

350	24. Reva ON, Sorokulova IB, Smirnov VV. 2001. Simplified technique for identification of the
351	aerobic spore-forming bacteria by phenotype. Int J Syst Evol Microbiol 51: 1361–1371.
352	25. Roberts MS, Nakamura LK, Cohan FM. 1994. Bacillus mojavensis sp. nov., distinguishable
353	from Bacillus subtilis by sexual isolation, divergence in DNA sequence, and differences in
354	fatty acid composition. Int J Syst Bacteriol 44: 256-264.
355	26. Goto K, Omura T, Hara Y, Sadaie Y. 2000 Application of the partial 16S rDNA sequence as
356	an index for rapid identification of species in the genus Bacillus. J Gen Appl Microbiol 46:
357	1-8.
358	27. National code of health research ethics FEDERAL MINISTRY OF HEALTH. In: Nhrec.net
359	[Internet]. [cited 7 Mar 2023]. Available: http://nhrec.net/nhrec/wp-
360	content/uploads/2018/10/NCHRE_Aug_07.pdf
361	28. Turnbull PCB. 1996. Bacillus. In: Baron S, editor. Medical Microbiology. 4th edition.
362	Galveston (TX): University of Texas Medical Branch at Galveston
363	29. Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, Bennett. 2014. principles and practice of
364	infectious diseases E-book. 8th ed. Saunders
365	30. La Jeon Y, Yang JJ, Kim MJ, Lim G, Cho SY, Park TS, Suh JT, Park YH, Lee MS, Kim SC,
366	Lee HJ. 2021. Combined Bacillus licheniformis and Bacillus subtilis infection in a patient
367	with oesophageal perforation. J Med Microbiol 61(Pt 12):1766-1769.
368	31. Michelotti F, Bodansky HJ. 2015. Bacillus cereus causing widespread necrotising skin
369	infection in a diabetic person. Pract Diabetes 32: 169–170a.
370	32. Orrett FA. 2000. Fatal Bacillus cereus bacteremia in a patient with diabetes. J Natl Med
371	Assoc 92:206–208.

372	33. Sandrin C, Peypoux F, Michel G. 1990. Coproduction of surfactin and iturin A, lipopeptides
373	with surfactant and antifungal properties, by Bacillus subtilis. Biotechnol Appl Biochem 12:
374	370–375.

375 34. Liu J, Li W, Zhu X, Zhao H, Lu Y, Zhang C, Lu Z. 2019. Surfactin effectively inhibits

Staphylococcus aureus adhesion and biofilm formation on surfaces. Appl Microbiol
Biotechnol 103(11):4565-4574.

378 35. Zhao H, Shao D, Jiang C, Shi J, Li Q, Huang Q, Rajoka MSR, Yang H, Jin M. 2017.

Biological activity of lipopeptides from Bacillus. Appl Microbiol Biotechnol 101(15):59515960.

381 36. Tao Y, Bie X-M, Lv F-X, Zhao H-Z, Lu Z-X. 2011. Antifungal activity and mechanism of

fengycin in the presence and absence of commercial surfactin against Rhizopus stolonifer. J
Microbiol 49:146–150.

384 37. Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. 2021.

385 Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other

pathogens: A systematic review and meta-analysis. PLoS One 16:e0251170.

38. Bahceci I, Yildiz IE, Duran OF, Soztanaci US, Kirdi Harbawi Z, Senol FF, Demiral G. 2022.

388 Secondary Bacterial Infection Rates Among Patients With COVID-19. Cureus 14(2):e22363.

389 39. Lansbury L, Lim B, Baskaran V, Lim WS. 2020. Co-infections in people with COVID-19: a

390 systematic review and meta-analysis. J Infect 81: 266–275.

40. Shafran N, Shafran I, Ben-Zvi H, Sofer S, Sheena L, Krause I, Shlomai A, Goldberg E, Sklan

EH. 2021. Secondary bacterial infection in COVID-19 patients is a stronger predictor for

death compared to influenza patients. Sci Rep 11(1):12703.

- 41. Davies-Bolorunduro OF, Fowora MA, Amoo OS, Adeniji E, Osuolale KA, Oladele O,
- 395 Onuigbo TI, Obi JC, Oraegbu J, Ogundepo O, Ahmed RA, Usman OA, Iyapo BG, Dada AA,
- 396 Onyia N, Adegbola RA, Audu RA, Salako BL. 2022. Evaluation of respiratory tract bacterial
- 397 co-infections in SARS-CoV-2 patients with mild or asymptomatic infection in Lagos,
- Nigeria. Bull Natl Res Cent. 46(1):115.